Recognition and elimination of malignant cells by cytotoxic T lymphocytes depends on antigenic peptides generated by proteasomes. It has been established that impairment of the immunoproteasome subunits, that is, PSMB8, PSMB9 and PSMB10 (PSMBs), is critical for malignant cells to escape immune recognition. We report here the regulatory mechanism of the repression of PU.1-dependent activation of PSMBs by PML/RARa in the pathogenesis of acute promyelocytic leukemia (APL) and the unidentified function of all-trans retinoic acid (ATRA) as an immunomodulator in the treatment of APL. Chromatin immunoprecipitation and luciferase reporter assays showed that PU.1 directly bound to and coordinately transactivated the promoters of PSMBs, indicating that PSMBs were transcriptional targets of PU.1 and PU.1 regulated their basal expression. Analysis of expression profiling data from a large population of acute myeloid leukemia (AML) patients revealed that the expression levels of PSMBs were significantly lower in APL patients than in non-APL AML patients. Further evidence demonstrated that the decrease in their expression was achieved through PML/RARa-mediated repression of both PU.1-dependent transactivation and PU.1 expression. Moreover, ATRA but not arsenic trioxide induced the expression of PSMBs in APL cells, indicating that ATRA treatment might activate the antigenprocessing/presentation machinery. Finally, the above observations were confirmed in primary APL samples. Collectively, our data demonstrate that PML/RARa suppresses PU.1-dependent activation of the immunosubunits, which may facilitate the escape of APL cells from immune surveillance in leukemia development, and ATRA treatment is able to reactivate their expression, which would promote more efficient T-cell-mediated recognition in the treatment.
INTRODUCTION
Acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML), is characterized by a typical t(15;17)(q22;q21) translocation occurring in almost all of the patients. The translocation results in a rearrangement between the promyelocytic leukemia (PML) gene and the retinoic acid receptor a (RARa) gene, generating the PML/RARa fusion protein capable of blocking the differentiation at the promyelocytic stage.
1,2 PML/RARa harbors the DNA-binding domain of RARa and recruits corepressor molecules with a high affinity, 3 thus acting as a strong transcriptional repressor for its target genes. 4 Clinically, APL has progressed from a highly fatal disease to a highly curable one with the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (As 2 O 3 ) in its treatment. As both drugs act by promoting the degradation of PML/RARa, 5, 6 the combination of ATRA plus As 2 O 3 leads to durable remission of APL. Interestingly, ATRA exerts its effects on APL cells mainly at the transcriptome level, whereas As 2 O 3 exercises its impact mainly at the proteome level. 7 Moreover, PML/RARa can interact with other transcription factors such as AP-1, 8 PU.1 9 and GATA-2, 10 and target genes that are primarily regulated by these transcription factors, hence further expanding the number of PML/RARa target genes. In addition, PML/RARa exists in multiple complexes, including homodimers, oligomers and heterodimers, 11 which have been shown to cause a more flexible DNA-binding specificity and create numerous additional genomic binding sites in comparison to wild-type RARa. The expanded genomic landscape of PML/RARa impacts on the regulation of genes involved in a variety of cellular functions, including differentiation, proliferation, apoptosis, cell cycle progression and ubiquitin-proteasome proteolysis. 12 One of the functions potentially affected, based on the exploration of verified PML/RARa binding sites, is that of the immunoproteasome.
The presentation of antigenic peptides to cytotoxic T lymphocytes (CTLs) is a crucial prerequisite for successful immune recognition and elimination of transformed cells. 13 Generally, interferon-g induces the expression of the unique catalytic immunosubunits, including PSMB8, PSMB9 and PSMB10. 14 The replacement of the constitutive subunits by these inducible immunosubunits leads to the formation of the immunoproteasome, which is responsible for promoting the generation of antigenic peptides and enhancing the recognition of target cells by CTLs. 15 However, malignant cells are predominantly characterized by the abnormal expression of immunosubunits, 16 which may contribute to the failure of the immune system to recognize these cells. In APL, several lines of evidence have demonstrated that human leukocyte antigens (HLAs) appear undetectable on the surface of APL cells, 17, 18 suggesting a potential mechanism for these cells to escape immune detection. Furthermore, another possible way in which APL cells avoid the immune surveillance is probably associated with the disruption of normal PML function. As wild-type PML is involved in the expression of proteins that has important roles in antigen presentation, 17 cells with disrupted PML function would be predicted to be defective in antigen processing and presentation. Moreover, studies have reported that ATRA can function as an immune modulator via triggering the expression of genes associated with antigen processing and presentation. 19 More importantly, ATRA treatment can also reactivate the immunogenicity of APL cells; 17, 20, 21 this is particularly so during ATRA maintenance therapy, 21 implicating that restoration of antigen presentation by ATRA may be essential for effective immune responses in APL treatment. The above observations indicate that the loss of expression of genes involved in antigen presentation contributes to the immune escape of APL cells and effective treatment strategies may enhance APL-specific immune responses. While reduced expression of HLAs and impaired PML function explain, in part, the immune escape of APL cells, there are other pathways that may also be critically affected.
In this study, we report that PU.1 directly regulates the basal expression of the immunoproteasome subunits PSMBs and that PML/RARa represses the expression of these subunits in APL. The repression is through interfering with PU.1-dependent transactivation and reducing the PU.1 expression in APL. Furthermore, treatment with ATRA restores the expression of PSMBs and induces the activity of the immunoproteasome. This study describes a critical role of PU.1 in the expression of the immunoproteasome subunits and suggests that the downregulation of these subunits by PML/RARa is an additional mechanism by which APL cells escape immune surveillance.
RESULTS
Both PML/RARa and PU.1 bind to the promoter regions of PSMBs in APL cells The development of cancer usually requires that malignant cells cannot be effectively recognized by the immune system. 16 To identify genes potentially participating in the immune escape of APL cells, we screened the PML/RARa targets that we previously identified from genome-wide studies. 9 Interestingly, we observed that PML/RARa binding was enriched in the promoter regions of all three genes encoding the immunosubunits, that is, PSMB8, PSMB9 and PSMB10 (Figure 1a ), indicating that they were putative PML/RARa targets. To verify this finding, we performed chromatin immunoprecipitation quantitative real-time PCR (ChIP-qPCR) assays in APL-derived NB4 cells using primers encompassing the peak regions of the three genes and antibodies against PML and RARa. As expected, an enrichment of PML/RARa binding was observed at all promoter regions of PSMBs (Figure 1b) , consistent with the results obtained from the ChIP-sequencing analysis. The degree of enrichment differed among these promoters: ChIP enrichment was strongest for PSMB8, followed by PSMB10, whereas moderate enrichment was observed for PSMB9, indicating that the binding affinity might vary among these genes. As PML/RARa selectively targets PU.1-regulated genes, 9 we performed ChIP-qPCR assays in NB4 cells to determine whether PU.1 binds to the promoters of PSMBs in vivo. The chromatin DNA immunoprecipitated by anti-PU.1 antibody was amplified with the same primer sets used in the PML and RARa immunoprecipitates. As illustrated in Figure 1c , PU.1 binding was enriched at the same regions bound by PML/RARa. We also observed that the enrichment of PU.1 binding was in the order PSMB84PSMB104PSMB9. Taken together, the data suggest that both PML/RARa and PU.1 bind to the promoters of the immunosubunit genes in APL cells.
PU.1 regulates the basal expression of PSMBs in hematopoietic cells Next, we analyzed the nucleotide sequences around the promoter regions of PSMBs using the TRANSFAC software (Biobase, Braunschweig, Germany). As shown in Figure 2a , each of the PSMB promoters harbored at least one putative PU.1 binding site and multiple retinoic acid response element (RARE) half-sites adjacent to the peak center positions in the PML/RARa-and PU.1-enriched ChIP regions. The data support the above results that both PU.1 and PML/RARa bind to the promoters of PSMBs (Figures 1b and c) and also raise the possibility that PU.1 and PML/RARa can coregulate the expression of PSMBs. To determine whether the promoters of the immunosubunit genes are primarily targeted by PU.1 or, alternatively, PU.1 is recruited to these promoters by PML/RARa, we performed two panels of ChIP-qPCR assays in PR9, a PML/RARa-inducible cell line. of PML/RARa (left panel), whereas PML/RARa binding was only enriched after PML/RARa induction (middle and right panels), indicating that PU.1 primarily bound to these promoters. In addition, we found that the degree of enrichment among the three promoters was consistent with the data from NB4 cells.
The above data suggest that PSMBs may be initially bound and coordinately regulated by PU.1. Next, to investigate whether PU.1 transactivates the promoters of PSMBs, we conducted promoterreporter assays in 293T cells, a non-hematopoietic cell line that does not express endogenous PU.1. After co-transfecting increasing amounts of the PU.1 expression construct, we found that the three promoters were transactivated by PU.1 in a dose-dependent manner (Figure 2c ), demonstrating that PU.1 directly regulated the transcription of PSMBs. To further elucidate the role of the PU.1 sites in the transcriptional regulation of the three promoters in hematopoietic cells, we mutated these PU.1 sites one by one and compared promoter activities of these mutants with their corresponding wild-type promoters in U937, which endogenously expresses PU.1. As illustrated in Figure 2d , the mutation at the second PU.1 site ( À 1 to þ 7 bp) severely impaired promoter activity of PSMB8, while the mutation at the first PU.1 site ( À 476 to À 468 bp) exhibited only moderate effects on promoter activity. When both PU.1 sites were mutated, promoter activity was abolished, indicating that both sites in the PSMB8 promoter were required for PU.1-dependent transactivation. Similarly, we also observed that the mutation of the PU.1 site resulted in a significant reduction of the PSMB9 and PSMB10 promoter activities, respectively. These results indicate that PU.1 transactivates the promoters of PSMBs and the PU.1 sites located within their promoters are essential for promoter activity.
PML/RARa represses the expression of the immunosubunit genes
We are further interested in whether PML/RARa binding to the promoters of PSMBs influences their expression in APL cells. We thus first compared the expression of PSMBs in PML/RARa-positive and PML/RARa-negative hematopoietic cells. As illustrated in Figure 3a , the expression levels of PSMBs in PML/RARa-positive cells (NB4) were significantly lower than those in PML/RARanegative cells (U937, HL-60 and Kasumi-1), indicating that their expression was inversely correlated with PML/RARa expression. Next, we performed luciferase reporter assays on U937 cells in the presence and absence of PML/RARa and found that the relative luciferase activities of PSMBs decreased after co-transfection of PML/RARa into U937 cells (Figure 3b ), demonstrating that PML/ RARa repressed promoter activities of the immunosubunit genes. Downregulation of PSMBs in APL is achieved through the repression of PU.1-dependent transactivation of PSMBs and the reduced PU.1 expression by PML/RARa As the expression of PSMBs was primarily bound and regulated by PU.1 (Figures 2b and c) , we hypothesized that the reduced expression of PSMBs in APL cells might be mediated by PU.1. To test this hypothesis, we conducted luciferase reporter assays on 293T cells to evaluate promoter activities of PSMBs in the presence and absence of PML/RARa and PU.1. As shown in Figure 4a , PML/ RARa alone caused minor/minimal changes in the luciferase activities of these promoters, whereas PU.1 significantly enhanced luciferase activities, revealing a PU.1-dependent transactivation of the promoters of PSMBs. More importantly, co-transfection of PML/RARa effectively suppressed PU.1-dependent transactivation, indicating that PML/RARa functioned as an effective repressor only under the presence of PU.1. In addition, as PU.1 expression itself can be reduced by PML/RARa in APL cells, 9, 12, 22 we speculated that the low PU.1 expression in APL might also contribute to the low expression of PSMBs and ectopic expression of PU.1 would be able to restore the expression of PSMBs in APL cells. As shown in Figure 4b , we observed that the expression of PSMBs significantly increased after ectopic expression of PU.1. In addition, we performed luciferase reporter assays and found that PU.1 overexpression resulted in an obvious increase in promoter activities of PSMBs (Figure 4c) . Collectively, the data indicate that downregulation of PSMBs in APL is achieved through PML/RARamediated repression of both PU.1-dependent transactivation and PU.1 expression. expression of PSMBs following treatment of NB4 cells with ATRA or As 2 O 3 . As shown in Figures 5a and b , the expression of PSMBs was upregulated at both mRNA and protein levels after ATRA treatment and the increase was maintained up to 72 h. In contrast, As 2 O 3 only caused minor/minimal changes in their expression. As the expression of PSMBs is dependent on PU.1, the difference in the effects of ATRA and As 2 O 3 is probably due to the difference in PU.1 expression influenced by the two drugs. We thus further measured PU.1 expression after ATRA or As 2 O 3 treatment. As shown in Figure 5c , ATRA significantly increased PU.1 expression, whereas As 2 O 3 hardly affected its expression. We also performed luciferase reporter assays in NB4 cells to verify the responsiveness of the promoters of PSMBs to ATRA or As 2 O 3 . As shown in Figure 5d , an obvious increase in promoter activities of PSMBs was observed after ATRA treatment, whereas their promoter activities were less influenced or even inhibited by As 2 O 3 treatment, consistent with the above observation (Figures 5a and b) . Induction of the expression of immunosubunits may result in a change in proteasome activity. Therefore, we compared the peptidase activity of the immunosubunits in NB4 cells before and after ATRA treatment. As illustrated in Figure 5e , a significant increase in peptidase activity was detected after 48 h of ATRA treatment and maintained throughout the rest of the experimental period. The data indicate that ATRA but not As 2 O 3 has the ability to induce the expression of the immunosubunits and relieve the PML/RARa-mediated repression, which might activate the antigen-processing/presentation machinery.
ATRA but not As
Evidence for the targeting and regulation of PSMBs by PU.1 and PML/RARa in primary APL cells Using a series of cell lines, we determined that PSMBs were primarily bound and regulated by PU.1, and PML/RARa targeted and repressed their expression. To further verify these observations in primary clinical samples, we isolated mononuclear cells from two newly diagnosed primary APL patient samples with high percentages of blasts (91% and 98%, respectively) and performed ChIP-qPCR with antibodies against RARa and PU.1. As shown in Figure 6a , both PML/RARa and PU.1 bound to the promoters of PSMBs, consistent with the data shown in Figures 1b and c. Next, to investigate whether this binding interferes with the expression of the immunosubunits in primary APL patients, we compared the mRNA expression of PSMBs using qRT-PCR in blast cells from four primary APL patient samples with the peripheral blood cells from six healthy volunteers and normal hematopoietic stem cell-enriched CD34 þ cells separated from four fresh human UCB specimens. As shown in Figure 6b , the expression of PSMBs was significantly lower in primary APL samples than in normal hematopoietic cells, including white blood cells, mononuclear cells, granulocytes and immature progenitor cells. The results indicated that the immunosubunits were suppressed in primary APL patients, confirming the inverse correlation between PML/RARa and the immunosubunits. To further test this concept in a large cohort of samples, we retrieved three data sets of the AML expression profiling, [23] [24] [25] including 73 APL patients and 640 AML patients with other subtypes, and compared the expression of PSMBs between PML/RARa-positive and PML/RARa-negative AML patient samples. As shown in Figure 6c , the large-scale gene expression analysis clearly revealed that PSMBs were expressed at a lower level in APL patients than in non-APL AML patients. We also detected PU.1 expression in this cohort of patient samples. As expected, PU.1 expression was significantly repressed in APL samples. The data are compliant with our findings from the cell line that the expression of the immunosubunits is downregulated by PML/ RARa in primary APL patients and the repression is mediated by PU.1 (Figures 3 and 4) . As AML is a group of diseases characterized by the abnormal development of malignant myeloid cells, we are interested in the expression of PSMBs and PU.1 in the other subtypes, including those with normal and abnormal karyotypes. We divided the AML samples into nine groups according to the French-American-British classification and karyotype status (that is, normal vs abnormal), and evaluated the expression of PSMBs and PU.1 in each specific group. Interestingly, we found that the expression of PSMBs and PU.1 was lower in M3 (PML/RARa-positive APL) than in other subtypes whether the karyotype of the specimen was normal or not (Supplementary Figure S1) , further confirming that the expression of the immunosubunits were specifically downregulated with the expression of PML/RARa and reduced PU.1 expression in APL. In addition, we also treated samples from two newly diagnosed APL patients with ATRA and found their expression levels were upregulated after ATRA treatment (Figure 6d ), in accordance with the results observed in NB4 cells. Taken together, the results from primary clinical samples validate the observations obtained with the cell lines.
DISCUSSION
The impairment of antigen presentation is one of the main mechanisms that malignant cells use to escape the CTL-mediated immune surveillance. The immunosubunits that are composed of PSMB8, PSMB9 and PSMB10 function as the proteolytically active subunits of the immunoproteasome, and the coordinated incorporation of the three immunosubunits into the proteasome complex has a pivotal role in antigen generation/processing. In this study, we demonstrated that all three immunosubunits were primarily bound and regulated by PU.1, and then targeted and repressed by the PML/RARa fusion protein in APL.
Our results provide new insights into the regulatory mechanism of the basal expression of the immunosubunit genes. It has been reported that the expression of the immunosubunits can be upregulated by inducing signals such as interferon-g and tumor necrosis factor a, 26 yet the key transcription factors that are essential for their basal expression have not been identified. Here, we observed that the hematopoietic specific transcription factor PU.1 was required for the basal expression of the immunosubunits in hematopoietic cells. PU.1 is believed to contribute predominantly to hematopoietic development. PU.1-deficient mice exhibit maturation arrest of macrophages and granulocytes. 27 Recently, growing evidence has suggested a role for PU.1 in the generation of innate and adaptive immune cells. 28, 29 For instance, PU.1 is capable of functioning as a transcriptional regulator in determining the fate of immunocytes such as lymphocyte and dendritic cell lineages. [30] [31] [32] Moreover, PU.1 critically participates in enhancing the expression of the costimulatory molecules on the cell surface. PU.1 increases the expression of CD80 and CD86, two important cell surface markers on dendritic cells, through directly binding to their promoter regions, facilitating the CTL-mediated activation. 33 In addition to the signals from costimulatory molecules, the effective recognition and activation of antigenpresenting cells also require a stronger major histocompatibility complex (MHC)/antigen activation signal from antigen-presenting cells. 34 The level of MHC molecules largely depends on the expression of the functional immunoproteasome. Here, we demonstrated that PU.1 participated in regulating the expression of antigen presentation genes. The expression levels of the immunosubunits were primarily regulated by PU.1 through direct binding in hematopoietic cells (Figure 2b) . Our results indicate that the concerted upregulation of the immunosubunits by PU.1 may enhance the density of the MHC complex on the cell surface, yielding an elevated efficacy of CTL activation.
Previous studies have demonstrated that antigen presentation processes are defective in APL cells. For example, HLAs are hardly detected on the surface of APL cells. 17, 35, 36 Studies on the expression of the immunosubunits have shown that the APL cell line NB4 exhibits barely detectable PSMB8 and PSMB9 levels.
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PSMB10 expression data were absent from that study because PSMB10, unlike PSMB8 and PSMB9, is located outside of the MHC cluster, 37 and was therefore not identified during the investigation. However, the critical mechanism by which the expression of the immunosubunits is inhibited remains unclear. We revealed that PML/RARa bound the promoter regions of PSMBs (Figures 1b and  2b) , resulting in the repression of PU.1-dependent transactivation of PSMBs. In contrast, PML/RARa alone exerted minor effects on the repression of these promoters (Figure 4a) . Furthermore, through comparing the PML/RARa-positive and PML/RARa-negative AML patient samples, we observed the low expression levels of PSMBs in PML/RARa-positive APL samples, confirming the inverse correlation between PML/RARa and the immunosubunits. These results suggest that the inhibition of PSMBs may result in the defects of antigen presentation in APL and affect recognition of APL cells by CTLs, thereby allowing leukemia cells to escape from the host immune response.
ATRA and As 2 O 3 , as two drugs in clinical use for APL, both show favorable curative effects on the treatment of APL. ATRA plus conventional chemotherapy is currently the standard treatment strategy. 38 As 2 O 3 is also considered as front-line therapy for APL in some areas. 39 More importantly, a combination of ATRA plus As 2 O 3 performs even better than treatment with ATRA alone or As 2 O 3 alone 40 and represents the most successful therapeutic strategy for a hematopoietic malignant disease. Recent studies have demonstrated that As 2 O 3 may prevent relapse of APL by eradicating leukemia-initiating cells, 41 providing evidence that the combination is better than ATRA treatment alone. Our data likely indicate that ATRA but not As 2 O 3 has the ability to induce the expression of the immunosubunits, which may lead to the activation of the antigen-processing/presentation machinery and ultimately elicit a host response to kill malignant cells. Thus, from a clinical point of view, our finding supports the use of combination therapy, rather than As 2 O 3 alone, as the added potential for immune stimulation is likely to improve overall outcome.
Numerous studies have demonstrated that ATRA exerts pleiotropic effects on a variety of biological processes. Among them, the roles in differentiation induction, cell growth arrest and apoptosis are well documented. [42] [43] [44] [45] However, sparse data are available regarding its effects on the immune response. We demonstrated here that ATRA was also able to function as an immune modulator, which could contribute to the clinical outcome by immune elimination of leukemic cells. This observation is consistent with a previous study on ATRA-treated neuroblastoma, 19 where ATRA induced the systematic modulation of antigen presentation through upregulating multiple steps in the MHC class I presentation pathway in non-professional antigenpresenting cells transformed from cancer cells. Moreover, the increased expression of MHC class I molecules on the surface of target cells subsequently promoted T-cell-mediated recognition and killing. Indeed, using an APL-transplantable mouse model, Padua et al. 20 have shown that ATRA treatment combined with DNA vaccine can activate the T-cell response and increase the cytokine release, whereas the CTL responses cannot be detected in APL mice only with DNA vaccine treatment. In summary, our findings support the fact that the restoration of the immunosubunits by ATRA is a crucial prerequisite in the effective antigen presentation and leukemia-specific CTL responses.
Our findings not only reveal a previously unidentified role of ATRA in APL treatment but also suggest a potential clinical use of ATRA in the treatment of non-APL AML. The potential significance of our study is indeed supported by clinical trials, in which ATRA given after intensive chemotherapy significantly improved the outcome of older patients with non-APL AML. 46 Our study may present an additional layer of mechanisms of ATRA as an immune modulator in treating non-APL AML, in addition to the reported potential mechanisms such as through repression of the antiapoptotic protein BCL2 47 or survivin. 48 Taken together, the immunomodulating property of ATRA may be one of the potential mechanisms underlying effective treatment of APL, and the identification of therapeutic concepts that contribute to the success of APL therapy will be vital to the further improvement of the treatment protocols and even to its potential application in treating other cancers.
MATERIALS AND METHODS

Cell culture and reagents
Kasumi-1, U937, U937-PR9, HL-60 and NB4 cells were cultured in RPMI 1640 (Gibco, Carlsbad, CA, USA) containing 10% fetal bovine serum (Gibco). The 293T cells were cultured in DMEM (Gibco) containing 10% fetal bovine serum. Cells were grown in an incubator at 37 1C and 5% CO 2 . ZnSO 4 (Sigma, St Louis, MO, USA), ATRA (Sigma) and As 2 O 3 (Sigma) were used at final concentrations of 100, 1 and 1 mM, respectively.
Plasmid constructions and site-directed mutagenesis
The promoter regions of PSMBs were amplified from U937 cells by PCR with the corresponding primers and the resulting PCR fragments were cloned between the XhoI and HindIII sites of the luciferase reporter vector pGL4-basic (Promega, Madison, WI, USA), generating the plasmids PSMBs (wild-type). Mutations of the PU.1 binding sites in the three promoters were made using the QuikChange Site-directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) following the manufacturer's protocol. Detailed primer information is available in Supplementary Table S1. RNA extraction, qRT-PCR, western blot and proteolytic activity assays RNA was extracted using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and cDNA was reverse transcribed using the SuperScript II Reverse Transcriptase (Invitrogen) with random hexamer primers according to the manufacturer's protocol. The qRT-PCR assays were performed using the SYBR Green PCR Master Mix (Toyobo, Osaka, Japan) and the ABI 7900 HT Sequence Detection System (Applied Biosystems Inc., Foster City, CA, USA). Glyceraldehyde 3-phosphate dehydrogenase was used as an internal control. The relative mRNA expression level of the target gene in each sample was analyzed according to the comparative cycle time (Ct) method. 49 Each experiment was performed in triplicate. Detailed primer information is available in Supplementary Table S2 . To measure the protein levels of PSMBs, NB4 cell nuclear extracts were prepared and western blotting was performed. The detailed procedure was described previously. 50 The proteolytic activity of the immunoproteasome was analyzed using the Proteasome-GloTM Cell-Based Assay (Promega) according to the manufacturer's instructions.
Transient transfection and luciferase assays
Suspension cells (U937 and NB4) were electrotransfected using the electroporation generator ECM830 system (BTX, Holliston, MA, USA); adherent cells (293T) were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. The detailed procedure was described previously. 51 Luciferase assays were performed with the Dual-Luciferase Reporter Assay (Promega) 24 h after transfection. Luciferase activities were corrected for transfection efficiency by cotransfecting a plasmid expressing Renilla luciferase.
ChIP analysis
ChIP was performed according to the Affymetrix protocol as described, 52 with the following antibodies: anti-RARa (C-20 X; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-PML (H238 X; Santa Cruz), anti-PU.1 (T-21 X; Santa Cruz) and the rabbit immunoglobulin G (ab46540; Abcam, Cambridge, UK). qPCR was performed using the SYBR Green PCR Master Mix (Toyobo) and the ABI 7900 HT Sequence Detection System (Applied Biosystems Inc.). The fold enrichment of chromatin-immunoprecipitated PCR product relative to the input PCR product was calculated as described previously. 9 Detailed primer information is available in Supplementary Table S3 .
Patient samples and normal hematopoietic specimens
This study was approved by the institutional ethics committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine and was performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all patients and healthy donors. APL blasts were obtained at initial diagnosis from patient bone marrow samples. Peripheral blood specimens were obtained from healthy volunteers. Detailed information about APL patients is presented in Supplementary  Table S4 .
Gene expression analysis
Three transcriptome data sets for AML patients performed by Wouters et al. 23 (GSE14468), Tomasson et al. 25 (GSE10358) and Ross et al. 24 (St Jude) were pooled to compare the expression levels of immunosubunits between APL and non-APL patient samples. GSE14468 and GSE10358 were obtained from the Gene Expression Omnibus. St Jude was obtained from the website at http://www.stjuderesearch.org/data/AML1. To perform interarray comparisons, the CEL files were analyzed by Affymetrix MAS 5.0 software (Affymetrix, Santa Clara, CA, USA). Two-tailed t-tests were used to validate the significance of the observed differences, which were considered statistically significant when Po0.05.
Statistical analysis
The data were analyzed statistically using the Student's t-test. A P-value o0.05 was considered statistically significant.
